» Articles » PMID: 19343478

Natural History of Transfusion-independent Non-severe Aplastic Anemia in Children

Overview
Journal Int J Hematol
Specialty Hematology
Date 2009 Apr 4
PMID 19343478
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Although the known clinical courses of non-severe aplastic anemia (NSAA) in children comprise spontaneous resolution, persistent NSAA, or progression to severe aplastic anemia (SAA), only a few published reports have indicated the outcome of transfusion-independent NSAA. We retrospectively evaluated the incidence and time of progression from transfusion-independent to transfusion-dependent NSAA or SAA. We reviewed the records of 70 children with acquired AA who were referred to our hospital between 1986 and 2006, and among them we found 22 patients who had transfusion-independent NSAA at diagnosis and were treated with supportive care alone until progression to transfusion-dependent AA. 22 patients were followed up for a median of 86 months (range, 11-198 months). The Kaplan-Meier estimates for progression-free survival were 62 +/- 12 and 22 +/- 13% at 60 and 120 months after diagnosis, respectively. None of the patients treated with supportive care alone improved hematologically. In conclusion, because the incidence of disease progression was high in patients with NSAA, a prospective randomized trial of early intervention with IST or observation alone until disease progression to SAA, followed by IST when the patients become transfusion-dependent is warranted.

Citing Articles

Adding hetrombopag to cyclosporine a improved response of patients with newly diagnosed transfusion-dependent non-severe aplastic anemia.

Shen S, Hu Q, Yang C, Jiang Z, Chen M, Han B Ann Hematol. 2024; 103(10):4247-4249.

PMID: 39177798 DOI: 10.1007/s00277-024-05941-3.


A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study).

Vallejo C, Rosell A, Xicoy B, Garcia C, Albo C, Polo M Ann Hematol. 2024; 103(3):705-713.

PMID: 38175253 DOI: 10.1007/s00277-023-05602-x.


Comparison of anti-thymocyte globulin-based immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent non-severe aplastic anaemia: a retrospective study from a single centre.

Shen Y, Li Y, Liu Q, Liu W, Yu Q, Hu H Ann Med. 2023; 55(2):2271475.

PMID: 37871262 PMC: 10595398. DOI: 10.1080/07853890.2023.2271475.


Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic.

Zhang Y, He Y, Wang S, Sun J, Jia J, Gong Y Front Immunol. 2023; 14:1197982.

PMID: 37497227 PMC: 10366594. DOI: 10.3389/fimmu.2023.1197982.


Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.

Zhang L, Mao J, Lian Y, Liang Q, Li W, Zhao J Ann Hematol. 2023; 102(3):529-539.

PMID: 36680600 PMC: 9862246. DOI: 10.1007/s00277-023-05097-6.


References
1.
Kojima S, Inaba J, Yoshimi A, Takahashi Y, Watanabe N, Kudo K . Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001; 114(3):706-11. DOI: 10.1046/j.1365-2141.2001.02992.x. View

2.
Maciejewski J, Sloand E, Nunez O, Boss C, Young N . Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003; 102(10):3584-6. DOI: 10.1182/blood-2003-04-1032. View

3.
Khatib Z, Wilimas J, Wang W . Outcome of moderate aplastic anemia in children. Am J Pediatr Hematol Oncol. 1994; 16(1):80-5. View

4.
Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A . Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8. DOI: 10.3324/haematol.10075. View

5.
Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H . Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96(6):2049-54. View